Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Fahri Saatcioglu, Ph.D.

TitleVisiting Scientist
InstitutionHarvard School of Public Health
DepartmentGenetics and Complex Diseases
AddressHarvard School of Public Health
Genetics & Complex Diseases, Bldg 1-210
665 Huntington Ave
Boston MA 02115
Phone617/432-1956

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Saatcioglu F. Regulation of gene expression by yoga, meditation and related practices: A review of recent studies. Asian J Psychiatr. 2013 Feb; 6(1):74-7.
    View in: PubMed
  2. ten Freyhaus H, Calay ES, Yalcin A, Vallerie SN, Yang L, Calay ZZ, Saatcioglu F, Hotamisligil GS. Stamp2 controls macrophage inflammation through nicotinamide adenine dinucleotide phosphate homeostasis and protects against atherosclerosis. Cell Metab. 2012 Jul 3; 16(1):81-9.
    View in: PubMed
  3. Lazarevic B, Hammarström C, Yang J, Ramberg H, Diep LM, Karlsen SJ, Kucuk O, Saatcioglu F, Taskèn KA, Svindland A. The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. Br J Nutr. 2012 Dec; 108(12):2138-47.
    View in: PubMed
  4. Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Taskèn KA, Karlsen SJ. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer. 2011; 63(6):889-98.
    View in: PubMed
  5. Varisli L, Gonen-Korkmaz C, Debelec-Butuner B, Erbaykent-Tepedelen B, Muhammed HS, Bogurcu N, Saatcioglu F, Korkmaz KS. Ubiquitously expressed hematological and neurological expressed 1 downregulates Akt-mediated GSK3ß signaling, and its knockdown results in deregulated G2/M transition in prostate cells. DNA Cell Biol. 2011 Jun; 30(6):419-29.
    View in: PubMed
  6. Kirli HZ, Saatcioglu F. Methods to study dynamic interaction of androgen receptor with chromatin in living cells. Methods Mol Biol. 2011; 776:131-45.
    View in: PubMed
  7. Sikkeland J, Lindstad T, Saatcioglu F. Analysis of androgen-induced increase in lipid accumulation in prostate cancer cells. Methods Mol Biol. 2011; 776:371-82.
    View in: PubMed
  8. Arnoldussen YJ, Wang L, Saatcioglu F. Regulation of apoptosis by androgens in prostate cancer cells. Methods Mol Biol. 2011; 776:349-60.
    View in: PubMed
  9. Wang L, Jin Y, Arnoldussen YJ, Jonson I, Qu S, Maelandsmo GM, Kristian A, Risberg B, Waehre H, Danielsen HE, Saatcioglu F. STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. Cancer Res. 2010 Jul 15; 70(14):5818-28.
    View in: PubMed
  10. Lindstad T, Jin Y, Wang L, Qu S, Saatcioglu F. STAMPs at the crossroads of cancer and nutrition. Nutr Cancer. 2010; 62(7):891-5.
    View in: PubMed
  11. Kaarbø M, Mikkelsen OL, Malerød L, Qu S, Lobert VH, Akgul G, Halvorsen T, Maelandsmo GM, Saatcioglu F. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol. 2010; 32(1-2):11-27.
    View in: PubMed
  12. Arnoldussen YJ, Saatcioglu F. Dual specificity phosphatases in prostate cancer. Mol Cell Endocrinol. 2009 Oct 15; 309(1-2):1-7.
    View in: PubMed
  13. Arnoldussen YJ, Lorenzo PI, Pretorius ME, Waehre H, Risberg B, Maelandsmo GM, Danielsen HE, Saatcioglu F. The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res. 2008 Nov 15; 68(22):9255-64.
    View in: PubMed
  14. Lazarevic B, Karlsen SJ, Saatcioglu F. Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells. Oncol Rep. 2008 May; 19(5):1231-5.
    View in: PubMed
  15. Lorenzo PI, Saatcioglu F. Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. Neoplasia. 2008 May; 10(5):418-28.
    View in: PubMed
  16. Fladeby C, Gupta SN, Barois N, Lorenzo PI, Simpson JC, Saatcioglu F, Bakke O. Human PARM-1 is a novel mucin-like, androgen-regulated gene exhibiting proliferative effects in prostate cancer cells. Int J Cancer. 2008 Mar 15; 122(6):1229-35.
    View in: PubMed
  17. Kjellgren A, Bood SA, Axelsson K, Norlander T, Saatcioglu F. Wellness through a comprehensive yogic breathing program - a controlled pilot trial. BMC Complement Altern Med. 2007; 7:43.
    View in: PubMed
  18. Kaarbø M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays. 2007 Dec; 29(12):1227-38.
    View in: PubMed
  19. Lorenzo PI, Arnoldussen YJ, Saatcioglu F. Molecular mechanisms of apoptosis in prostate cancer. Crit Rev Oncog. 2007 Aug; 13(1):1-38.
    View in: PubMed
  20. Klokk TI, Kilander A, Xi Z, Waehre H, Risberg B, Danielsen HE, Saatcioglu F. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res. 2007 Jun 1; 67(11):5221-30.
    View in: PubMed
  21. Wellen KE, Fucho R, Gregor MF, Furuhashi M, Morgan C, Lindstad T, Vaillancourt E, Gorgun CZ, Saatcioglu F, Hotamisligil GS. Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell. 2007 May 4; 129(3):537-48.
    View in: PubMed
  22. Davidson B, Xi Z, Saatcioglu F. Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells. Diagn Cytopathol. 2007 Feb; 35(2):80-4.
    View in: PubMed
  23. Klokk TI, Kurys P, Elbi C, Nagaich AK, Hendarwanto A, Slagsvold T, Chang CY, Hager GL, Saatcioglu F. Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol. 2007 Mar; 27(5):1823-43.
    View in: PubMed
  24. Aslan G, Irer B, Tuna B, Yorukoglu K, Saatcioglu F, Celebi I. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features. Pathol Res Pract. 2006; 202(2):93-8.
    View in: PubMed
  25. Korkmaz CG, Korkmaz KS, Kurys P, Elbi C, Wang L, Klokk TI, Hammarstrom C, Troen G, Svindland A, Hager GL, Saatcioglu F. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene. 2005 Jul 21; 24(31):4934-45.
    View in: PubMed
  26. Davidson B, Xi Z, Klokk TI, Tropé CG, Dørum A, Scheistrøen M, Saatcioglu F. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions. Am J Clin Pathol. 2005 Mar; 123(3):360-8.
    View in: PubMed
  27. Frønsdal K, Saatcioglu F. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate. 2005 Feb 15; 62(3):299-306.
    View in: PubMed
  28. Lind GE, Skotheim RI, Fraga MF, Abeler VM, Henrique R, Saatcioglu F, Esteller M, Teixeira MR, Lothe RA. The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation. Mol Cancer. 2005 Feb 3; 4(1):8.
    View in: PubMed
  29. Korkmaz CG, Frønsdal K, Zhang Y, Lorenzo PI, Saatcioglu F. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants. J Endocrinol. 2004 Sep; 182(3):377-89.
    View in: PubMed
  30. Korkmaz CG, Korkmaz KS, Manola J, Xi Z, Risberg B, Danielsen H, Kung J, Sellers WR, Loda M, Saatcioglu F. Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J Urol. 2004 Sep; 172(3):1134-9.
    View in: PubMed
  31. Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Tropé C, Saatcioglu F. Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol. 2004 Jul; 94(1):80-5.
    View in: PubMed
  32. Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, Risberg B, Danielsen H, Loda M, Saatcioglu F. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 2004 Apr 1; 64(7):2365-70.
    View in: PubMed
  33. Skotheim RI, Korkmaz KS, Klokk TI, Abeler VM, Korkmaz CG, Nesland JM, Fosså SD, Lothe RA, Saatcioglu F. NKX3.1 expression is lost in testicular germ cell tumors. Am J Pathol. 2003 Dec; 163(6):2149-54.
    View in: PubMed
  34. Bratland A, Ragnhildstveit E, Bjørnland K, Andersen K, Maelandsmo GM, Fodstad O, Saatcioglu F, Ree AH. The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells. Clin Exp Metastasis. 2003; 20(6):541-7.
    View in: PubMed
  35. Berghagen H, Ragnhildstveit E, Krogsrud K, Thuestad G, Apriletti J, Saatcioglu F. Corepressor SMRT functions as a coactivator for thyroid hormone receptor T3Ralpha from a negative hormone response element. J Biol Chem. 2002 Dec 20; 277(51):49517-22.
    View in: PubMed
  36. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem. 2002 Sep 27; 277(39):36689-96.
    View in: PubMed
  37. Yamamoto T, Saatcioglu F, Matsuda T. Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology. 2002 Jul; 143(7):2635-42.
    View in: PubMed
  38. Engedal N, Korkmaz CG, Saatcioglu F. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene. 2002 Feb 7; 21(7):1017-27.
    View in: PubMed
  39. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem. 2001 Nov 16; 276(46):42908-14.
    View in: PubMed
  40. Korkmaz KS, Korkmaz CG, Pretlow TG, Saatcioglu F. Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones. DNA Cell Biol. 2001 Jul; 20(7):435-45.
    View in: PubMed
  41. Slagsvold T, Kraus I, Frønsdal K, Saatcioglu F. DNA binding-independent transcriptional activation by the androgen receptor through triggering of coactivators. J Biol Chem. 2001 Aug 17; 276(33):31030-6.
    View in: PubMed
  42. Thompson J, Saatcioglu F, Jänne OA, Palvimo JJ. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol Endocrinol. 2001 Jun; 15(6):923-35.
    View in: PubMed
  43. Matsuda T, Junicho A, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun. 2001 Apr 27; 283(1):179-87.
    View in: PubMed
  44. Engedal N, Saatcioglu F. Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features. Prostate. 2001 Mar 1; 46(4):289-97.
    View in: PubMed
  45. Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Kizildag S, Pretlow TG, Saatcioglu F. Full-length cDNA sequence and genomic organization of human NKX3A - alternative forms and regulation by both androgens and estrogens. Gene. 2000 Dec 30; 260(1-2):25-36.
    View in: PubMed
  46. Yamamoto T, Matsuda T, Junicho A, Kishi H, Saatcioglu F, Muraguchi A. Cross-talk between signal transducer and activator of transcription 3 and estrogen receptor signaling. FEBS Lett. 2000 Dec 8; 486(2):143-8.
    View in: PubMed
  47. Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun. 2000 Nov 11; 278(1):9-13.
    View in: PubMed
  48. Slagsvold T, Kraus I, Bentzen T, Palvimo J, Saatcioglu F. Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors. Mol Endocrinol. 2000 Oct; 14(10):1603-17.
    View in: PubMed
  49. Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Pretlow TG, Saatcioglu F. An efficient procedure for cloning hormone-responsive genes from a specific tissue. DNA Cell Biol. 2000 Aug; 19(8):499-506.
    View in: PubMed
  50. Thuestad G, Kraus I, Apriletti J, Saatcioglu F. The N-terminal domain of thyroid hormone receptor-alpha is required for its biological activities. DNA Cell Biol. 2000 Jul; 19(7):389-99.
    View in: PubMed
  51. Frønsdal K, Engedal N, Saatcioglu F. Efficient DNA-mediated gene transfer into prostate cancer cell line LNCaP. Prostate. 2000 May 1; 43(2):111-7.
    View in: PubMed
  52. Frønsdal K, Engedal N, Slagsvold T, Saatcioglu F. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem. 1998 Nov 27; 273(48):31853-9.
    View in: PubMed
  53. Saatcioglu F, Lopez G, West BL, Zandi E, Feng W, Lu H, Esmaili A, Apriletti JW, Kushner PJ, Baxter JD, Karin M. Mutations in the conserved C-terminal sequence in thyroid hormone receptor dissociate hormone-dependent activation from interference with AP-1 activity. Mol Cell Biol. 1997 Aug; 17(8):4687-95.
    View in: PubMed
  54. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem. 1997 Jul 11; 272(28):17485-94.
    View in: PubMed
  55. Kharat I, Saatcioglu F. Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor. Cross-talk between aryl hydrocarbon- and estrogen-mediated signaling. J Biol Chem. 1996 May 3; 271(18):10533-7.
    View in: PubMed
  56. Claret FX, Antakly T, Karin M, Saatcioglu F. A shift in the ligand responsiveness of thyroid hormone receptor alpha induced by heterodimerization with retinoid X receptor alpha. Mol Cell Biol. 1996 Jan; 16(1):219-27.
    View in: PubMed
  57. Rahman A, Esmaili A, Saatcioglu F. A unique thyroid hormone response element in the human immunodeficiency virus type 1 long terminal repeat that overlaps the Sp1 binding sites. J Biol Chem. 1995 Dec 29; 270(52):31059-64.
    View in: PubMed
  58. Saatcioglu F, Deng T, Karin M. A novel cis element mediating ligand-independent activation by c-ErbA: implications for hormonal regulation. Cell. 1993 Dec 17; 75(6):1095-105.
    View in: PubMed
  59. Saatcioglu F, Bartunek P, Deng T, Zenke M, Karin M. A conserved C-terminal sequence that is deleted in v-ErbA is essential for the biological activities of c-ErbA (the thyroid hormone receptor). Mol Cell Biol. 1993 Jun; 13(6):3675-85.
    View in: PubMed
  60. Saatcioglu F, Perry DJ, Pasco DS, Fagan JB. Multiple DNA-binding factors interact with overlapping specificities at the aryl hydrocarbon response element of the cytochrome P450IA1 gene. Mol Cell Biol. 1990 Dec; 10(12):6408-16.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Maria Maxell (mmaxellhsph.harvard.edu).
Saatcioglu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (361) concept(s)
_
Co-Authors
See all (4) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_